Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Fox Chase Cancer Center Huntingdon Pike
8 Huntingdon Pike
Rockledge, PA 19046
Chief, Division of Urology and Urologic Oncology
Professor, Department of Surgical Oncology
Roberta R. Scheller Chair in Urologic Oncology
American Urological Association's Urology Care Foundation, Prostate Health Committee Panel Member
Minimally Invasive Surgery, Robotic Surgery, Laparoscopic Surgery, Traditional Open Surgery
Prostate Cancer: robotic and open radical nerve-sparing prostatectomy
Bladder Cancer: urinary diversion, orthotopic neobladder reconstruction
Kidney Cancer: kidney-sparing approaches, robotic, laparoscopic, open kidney surgery.
Adrenal masses: minimally-invasive adrenal surgery and extensive expertise in treatment of adrenal incidentalomas.
I am a surgical specialist who treats tumors of the adrenal, kidney, prostate, bladder, testis, and other genitourinary organs. Working closely with other members of the Fox Chase multidisciplinary team, I make certain that my patients are aware of all the choices that today's cutting edge oncological care has to offer, regardless of whether these treatments take place inside or outside the operating room.
When surgery is necessary, I strive to offer the best operation that fits an individual's particular condition and circumstance. Indeed, my unique fellowship training in both traditional open surgery and minimally-invasive approaches such as laparoscopy and robotics, allows me to offer a wide range of options that optimize oncological outcomes and minimize recovery time. For example, I am skilled at both open and robot-assisted nerve-sparing prostatectomy and open, laparoscopic, and robotic kidney surgery. Particularly, I have advanced expertise in kidney preservation. For patients with bladder cancer, I am able to offer both bladder-sparing approaches and the latest techniques in continent urinary reconstruction. Furthermore, I have a particular interest and expertise in treatment of various tumors and conditions that stem from the adrenal gland.
As a clinician at an academic institution such as Fox Chase, I actively participate in medical research. In particular, my academic interests focus on kidney, prostate, bladder, and adrenal disease. Being an active contributor to the medical literature, I hope to offer my patients the most up-to-date information on medical progress and, if necessary, help them enroll into appropriate clinical trials — many of which are only available through Fox Chase.
Modern oncology offers patients tremendous hope; however, today's treatment options can be overwhelming, especially to those who are trying to cope with the shock of a recent cancer diagnosis. I greatly appreciate the toll that such a diagnosis can take not only on the patient, but also on his or her family. I hope to bring to every one of my patients a sense of understanding and compassion that can help us effectively work together to achieve the best outcome that modern medicine has to offer.
After being diagnosed with an aggressive form of prostate cancer, Joe Briggs sought treatment at Fox Chase Cancer Center, where he underwent a robotic prostatectomy. About three months after surgery, he was back to work and spending time with his family. He credits Fox Chase as being oat the forefront of cutting-edge treatment options for cancer. "Looking back, I am confident that Fox Chase was the best place for my care and that it was the best decision that we have made," Joe said. "I feel they are offering world-class treatment 30 minutes from my house. They use cutting-edge treatments that are performed by the brightest minds in health care who care about me and care about my wife and family."
At 81 years old, Victoria Mirarchi was still active and healthy before undergoing surgery at a local hospital to remove a large mass from her abdominal area. The mass was diagnosed as liposarcoma, an aggressive tumor. When the tumor returned twice, Victoria decided to seek a second opinion from the specialists at Fox Chase Cancer Center. Following the surgery at Fox Chase, Victoria is happy to report that the cancer has not returned. She said, "I am so happy everything went well, and I still go back to Fox Chase every few months to see Dr. Reddy. I wish nothing but the best for all the surgeons there, and keep them in my prayers daily."
Kidney cancer is something Arkady Shteyman has lived with since 1968. That's the year, when Arkady was 19, that his father died of the disease at the young age of 44.
"Because I have that history, I get regular ultrasounds," said the electronic technician, who immigrated to the Philadelphia region from the Ukraine in the former Soviet Union in 1990.
In June, 2012, Bil Sauer, an entrepreneur and owner of several businesses, was wrapping up a busy work week. It was late afternoon on a Friday, and his wife Laura and he were planning on spending the weekend at their lake home with their two teenage children Tom, 14, and Tehya, 18. “It was getting late so I told my wife and kids to go ahead and I would meet them there,” recalls Bil. He lost track of time and it was almost 7:00 pm before he left his Bucks County office. Bil decided he would drive up on Saturday morning instead.
At 54, Peggy McCaughey is counting her blessings. In addition to her husband, Hugh, and their two daughters, Hannah Rose and Grace Kelly, she feels blessed to be alive. "I am overjoyed to share my experience about Fox Chase Cancer Center,” she says.
Peggy's journey began with heavy menstrual periods, losing hair and back pain. She shared her concerns with her gynecologist who suggested hormone therapy. “I could not tolerate it,” Peggy recalls.
Dr. Kutikov has authored over 140 peer-reviewed publications. His current research interests include understanding carcinogenesis of genitourinary cancers, risk-stratification of surgical outcomes, and quantification of competing risks. He serves on editorial boards of academic journals, including being the Associate Editor of Digital Media for European Urology, the field of Urology's leading academic publication.
Dr. Kutikov also has significant interests in harnessing web and mobile technology to improve patient engagement and quality of care. He is a co-founder of several ventures that strive to improve physician education and patient care.
In collaboration with Vladimir Kolenko, MD, PhD, and Robert Uzzo, MD, our research efforts span the basic and the clinical sciences. Our work focuses on understanding the process of renal and prostatic carcinogenesis and assessing novel therapeutic regimens for the treatment of urological cancers.
As part of our work, we explore the role of zinc in development and progression of prostate malignancy. Zinc concentrations diminish early in the course of prostate carcinogenesis—prior to histopathological changes—and continue to decline during progression toward castration-resistant growth. The objective of research in our laboratory is to test and advance an emerging paradigm that intracellular zinc deficiency augments malignant potential of prostate cancer cells and, therefore, promotes prostate tumorigenesis. We are also investigating the role of zinc chelators as potential therapeutic agents for the treatment of castration-resistant prostate cancer. Work performed by Dr. Kolenko indicates that treatment of prostate cancer cells with the zinc chelating agent TPEN induces selective down-regulation of X-linked inhibitor of apoptosis protein (XIAP) and sensitizes cancer cells to cytotoxic agents. Importantly, the observed effect is not limited to prostate cancer, as TPEN reduces expression of XIAP in malignant cell lines of various origins, e.g. colon, ovarian, leukemia, breast and cervical.
The second major theme of our research is to determine the mechanism of tyrosine kinase inhibitor (TKIs)-resistance in genitourinary tumors. Our studies reveal that TKI-resistance coincides with the loss of phosphatase and tensin homolog (PTEN) protein expression in prostate and renal malignant cells. On the contrary, expression of PTEN sensitizes prostate and renal tumors to multi-targeted tyrosine kinase inhibitor sunitinib both in vitro and in vivo. In addition, our studies indicate that an increase in expression of IL-6 and IL-8 correlates with sunitinib and pazopanib resistance in prostate and renal tumor cells. Use of a reliable biomarker for TKI response, harbors promise both in the clinical and research settings.
In the clinical arena, we focus our efforts on addressing quantification of competing risks of death for patients with urologic malignancies, investigating the biology and natural history of small renal masses, improving reporting and risk-stratification of surgical outcomes for patients with kidney cancer, and addressing clinical approaches to patients with adrenal cancers and incidental adrenal masses.
A. G. McIntosh, D. C. Parker, B. L. Egleston, R. G. Uzzo, H. Haseebuddin, S. S. Joshi, R. Viterbo, R. E. Greenberg, D. Y. T. Chen, M. C. Smaldone, and Kutikov, “Prediction of Significant Estimated Glomerular Filtration Rate Decline Following Renal Unit Removal to Aid in the Clinical Choice between Radical and Partial Nephrectomy in Patients with Renal Mass and Normal Renal Function,” BJU Int, May 2019. PubMed
H. Borgmann, M. Cooperberg, D. Murphy, S. Loeb, J. N’Dow, M. J. Ribal, H. Woo, M. Rouprêt, A. Winterbottom, C. Wijburg, M. Wirth, J. Catto, and A. Kutikov, “Online Professionalism—2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media,” European Urology, pp. 1–7, Aug. 2018. PubMed
M. C. Smaldone, B. Egleston, J. M. Hollingsworth, B. K. Hollenbeck, D. C. Miller, T. M. Morgan, S. P. Kim, A. Malhotra, E. Handorf, Y.-N. Wong, R. G. Uzzo, and A. Kutikov, “Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data,” Med Care, vol. 55, no. 4, pp. 398–404, Apr. 2017. PubMed
N. Waingankar, K. Mallin, M. Smaldone, B. L. Egleston, A. Higgins, D. P. Winchester, R. G. Uzzo, and A. Kutikov, “Assessing the relative influence of hospital and surgeon volume on short-term mortality after radical cystectomy,” BJU Int, vol. 120, no. 2, pp. 239–245, Aug. 2017. PubMed
B. T. Ristau, D. Y. T. Chen, J. Ellis, A. Malhotra, L. DeMora, R. B. Parsons, B. Milestone, M. Brody, R. Viterbo, R. Greenberg, M. Smaldone, R. Uzzo, J. Anaokar, and A. Kutikov, “Defining Novel and Practical Metrics to Assess the Deliverables of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy,” The Journal of Urology, Oct. 2017. PubMed
S. P. Kim, S. C. Campbell, I. Gill, B. R. Lane, H. Van Poppel, M. C. Smaldone, A. Volpe, and A. Kutikov, “Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses,” European Urology, vol. 72, no. 1, pp. 64–75, Jul. 2017. PubMed
A. Kutikov, H. H. Woo, and J. W. Catto, “Urology Tag Ontology Project: Standardizing Social Media Communication Descriptors,” European Urology, vol. 69, no. 2, pp. 183–185, Feb. 2016. PubMed
A. Kutikov, M. C. Smaldone, R. G. Uzzo, M. Haifler, G. Bratslavsky, and B. C. Leibovich, “Renal Mass Biopsy: Always, Sometimes, or Never?,” European Urology, vol. 70, no. 3, pp. 403–406, Sep. 2016. PubMed
E. R. Plimack, R. L. Dunbrack, T. A. Brennan, M. D. Andrake, Y. Zhou, I. G. Serebriiskii, M. Slifker, K. Alpaugh, E. Dulaimi, N. Palma, J. Hoffman-Censits, M. Bilusic, Y.-N. Wong, A. Kutikov, R. Viterbo, R. E. Greenberg, D. Y. T. Chen, C. D. Lallas, E. J. Trabulsi, R. Yelensky, D. J. McConkey, V. A. Miller, E. A. Golemis, and E. A. Ross, “Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer,” European Urology, vol. 68, no. 6, pp. 959–967, Dec. 2015. PubMed
S. Ginzburg, R. Uzzo, J. Walton, C. Miller, D. Kurz, T. Li, E. Handorf, R. Gor, A. Corcoran, R. Viterbo, D. Y. T. Chen, R. E. Greenberg, M. C. Smaldone, and A. Kutikov, “Residual Parenchymal Volume, Not Warm Ischemia Time, Predicts Ultimate Renal Functional Outcomes in Patients Undergoing Partial Nephrectomy.,” Urology, vol. 86, no. 2, pp. 300–306, Aug. 2015. PubMed
B. Shuch, A. Amin, A. J. Armstrong, J. N. Eble, V. Ficarra, A. Lopez-Beltran, G. Martignoni, B. I. Rini, and A. Kutikov, “Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity,” European Urology, vol. 67, no. 1, pp. 85–97, Jan. 2015. PubMed
E. R. Plimack, J. H. Hoffman-Censits, R. Viterbo, E. J. Trabulsi, E. A. Ross, R. E. Greenberg, D. Y. T. Chen, C. D. Lallas, Y.-N. Wong, J. Lin, A. Kutikov, E. Dotan, T. A. Brennan, N. Palma, E. Dulaimi, R. Mehrazin, S. A. Boorjian, W. K. Kelly, R. G. Uzzo, and G. R. Hudes, “Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity,” J. Clin. Oncol., vol. 32, no. 18, pp. 1895–1901, Jun. 2014. PubMed
A. Minervini, M. Carini, R. G. Uzzo, R. Campi, M. C. Smaldone, and A. Kutikov, “Standardized Reporting of Resection Technique During Nephron-sparing Surgery: The Surface-Intermediate-Base Margin Score.,” European Urology, Jun. 2014. PubMed
A. Kutikov, P. Makhov, K. Golovine, D. J. Canter, M. Sirohi, R. Street, J. Simhan, R. G. Uzzo, and V. M. Kolenko, “Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer,” Urology, vol. 78, no. 4, pp. 968.e7–11, Oct. 2011. PubMed
A. Kutikov, M. C. Smaldone, B. L. Egleston, B. J. Manley, D. J. Canter, J. Simhan, S. A. Boorjian, R. Viterbo, D. Y. T. Chen, R. E. Greenberg, and R. G. Uzzo, “Anatomic Features of Enhancing Renal Masses Predict Malignant and High-Grade Pathology: A Preoperative Nomogram Using the RENAL Nephrometry Score,” European Urology, vol. 60, no. 2, pp. 241–248, Aug. 2011. PubMed
A. Kutikov, B. L. Egleston, Y.-N. Wong, and R. G. Uzzo, “Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram,” J. Clin. Oncol., vol. 28, no. 2, pp. 311–317, Jan. 2010. PubMed
A. Kutikov and R. G. Uzzo, “The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth,” The Journal of Urology, vol. 182, no. 3, pp. 844–853, Sep. 2009. PubMed
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Fox Chase Cancer Center Huntingdon Pike
8 Huntingdon Pike
Rockledge, PA 19046
Chief, Division of Urology and Urologic Oncology
Professor, Department of Surgical Oncology
Roberta R. Scheller Chair in Urologic Oncology
American Urological Association's Urology Care Foundation, Prostate Health Committee Panel Member
Minimally Invasive Surgery, Robotic Surgery, Laparoscopic Surgery, Traditional Open Surgery
Prostate Cancer: robotic and open radical nerve-sparing prostatectomy
Bladder Cancer: urinary diversion, orthotopic neobladder reconstruction
Kidney Cancer: kidney-sparing approaches, robotic, laparoscopic, open kidney surgery.
Adrenal masses: minimally-invasive adrenal surgery and extensive expertise in treatment of adrenal incidentalomas.
I am a surgical specialist who treats tumors of the adrenal, kidney, prostate, bladder, testis, and other genitourinary organs. Working closely with other members of the Fox Chase multidisciplinary team, I make certain that my patients are aware of all the choices that today's cutting edge oncological care has to offer, regardless of whether these treatments take place inside or outside the operating room.
When surgery is necessary, I strive to offer the best operation that fits an individual's particular condition and circumstance. Indeed, my unique fellowship training in both traditional open surgery and minimally-invasive approaches such as laparoscopy and robotics, allows me to offer a wide range of options that optimize oncological outcomes and minimize recovery time. For example, I am skilled at both open and robot-assisted nerve-sparing prostatectomy and open, laparoscopic, and robotic kidney surgery. Particularly, I have advanced expertise in kidney preservation. For patients with bladder cancer, I am able to offer both bladder-sparing approaches and the latest techniques in continent urinary reconstruction. Furthermore, I have a particular interest and expertise in treatment of various tumors and conditions that stem from the adrenal gland.
As a clinician at an academic institution such as Fox Chase, I actively participate in medical research. In particular, my academic interests focus on kidney, prostate, bladder, and adrenal disease. Being an active contributor to the medical literature, I hope to offer my patients the most up-to-date information on medical progress and, if necessary, help them enroll into appropriate clinical trials — many of which are only available through Fox Chase.
Modern oncology offers patients tremendous hope; however, today's treatment options can be overwhelming, especially to those who are trying to cope with the shock of a recent cancer diagnosis. I greatly appreciate the toll that such a diagnosis can take not only on the patient, but also on his or her family. I hope to bring to every one of my patients a sense of understanding and compassion that can help us effectively work together to achieve the best outcome that modern medicine has to offer.
Follow on Twitter: @uretericbud
Dr. Kutikov has authored over 140 peer-reviewed publications. His current research interests include understanding carcinogenesis of genitourinary cancers, risk-stratification of surgical outcomes, and quantification of competing risks. He serves on editorial boards of academic journals, including being the Associate Editor of Digital Media for European Urology, the field of Urology's leading academic publication.
Dr. Kutikov also has significant interests in harnessing web and mobile technology to improve patient engagement and quality of care. He is a co-founder of several ventures that strive to improve physician education and patient care.
In collaboration with Vladimir Kolenko, MD, PhD, and Robert Uzzo, MD, our research efforts span the basic and the clinical sciences. Our work focuses on understanding the process of renal and prostatic carcinogenesis and assessing novel therapeutic regimens for the treatment of urological cancers.
As part of our work, we explore the role of zinc in development and progression of prostate malignancy. Zinc concentrations diminish early in the course of prostate carcinogenesis—prior to histopathological changes—and continue to decline during progression toward castration-resistant growth. The objective of research in our laboratory is to test and advance an emerging paradigm that intracellular zinc deficiency augments malignant potential of prostate cancer cells and, therefore, promotes prostate tumorigenesis. We are also investigating the role of zinc chelators as potential therapeutic agents for the treatment of castration-resistant prostate cancer. Work performed by Dr. Kolenko indicates that treatment of prostate cancer cells with the zinc chelating agent TPEN induces selective down-regulation of X-linked inhibitor of apoptosis protein (XIAP) and sensitizes cancer cells to cytotoxic agents. Importantly, the observed effect is not limited to prostate cancer, as TPEN reduces expression of XIAP in malignant cell lines of various origins, e.g. colon, ovarian, leukemia, breast and cervical.
The second major theme of our research is to determine the mechanism of tyrosine kinase inhibitor (TKIs)-resistance in genitourinary tumors. Our studies reveal that TKI-resistance coincides with the loss of phosphatase and tensin homolog (PTEN) protein expression in prostate and renal malignant cells. On the contrary, expression of PTEN sensitizes prostate and renal tumors to multi-targeted tyrosine kinase inhibitor sunitinib both in vitro and in vivo. In addition, our studies indicate that an increase in expression of IL-6 and IL-8 correlates with sunitinib and pazopanib resistance in prostate and renal tumor cells. Use of a reliable biomarker for TKI response, harbors promise both in the clinical and research settings.
In the clinical arena, we focus our efforts on addressing quantification of competing risks of death for patients with urologic malignancies, investigating the biology and natural history of small renal masses, improving reporting and risk-stratification of surgical outcomes for patients with kidney cancer, and addressing clinical approaches to patients with adrenal cancers and incidental adrenal masses.
A. G. McIntosh, D. C. Parker, B. L. Egleston, R. G. Uzzo, H. Haseebuddin, S. S. Joshi, R. Viterbo, R. E. Greenberg, D. Y. T. Chen, M. C. Smaldone, and Kutikov, “Prediction of Significant Estimated Glomerular Filtration Rate Decline Following Renal Unit Removal to Aid in the Clinical Choice between Radical and Partial Nephrectomy in Patients with Renal Mass and Normal Renal Function,” BJU Int, May 2019. PubMed
H. Borgmann, M. Cooperberg, D. Murphy, S. Loeb, J. N’Dow, M. J. Ribal, H. Woo, M. Rouprêt, A. Winterbottom, C. Wijburg, M. Wirth, J. Catto, and A. Kutikov, “Online Professionalism—2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media,” European Urology, pp. 1–7, Aug. 2018. PubMed
M. C. Smaldone, B. Egleston, J. M. Hollingsworth, B. K. Hollenbeck, D. C. Miller, T. M. Morgan, S. P. Kim, A. Malhotra, E. Handorf, Y.-N. Wong, R. G. Uzzo, and A. Kutikov, “Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data,” Med Care, vol. 55, no. 4, pp. 398–404, Apr. 2017. PubMed
N. Waingankar, K. Mallin, M. Smaldone, B. L. Egleston, A. Higgins, D. P. Winchester, R. G. Uzzo, and A. Kutikov, “Assessing the relative influence of hospital and surgeon volume on short-term mortality after radical cystectomy,” BJU Int, vol. 120, no. 2, pp. 239–245, Aug. 2017. PubMed
B. T. Ristau, D. Y. T. Chen, J. Ellis, A. Malhotra, L. DeMora, R. B. Parsons, B. Milestone, M. Brody, R. Viterbo, R. Greenberg, M. Smaldone, R. Uzzo, J. Anaokar, and A. Kutikov, “Defining Novel and Practical Metrics to Assess the Deliverables of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy,” The Journal of Urology, Oct. 2017. PubMed
S. P. Kim, S. C. Campbell, I. Gill, B. R. Lane, H. Van Poppel, M. C. Smaldone, A. Volpe, and A. Kutikov, “Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses,” European Urology, vol. 72, no. 1, pp. 64–75, Jul. 2017. PubMed
A. Kutikov, H. H. Woo, and J. W. Catto, “Urology Tag Ontology Project: Standardizing Social Media Communication Descriptors,” European Urology, vol. 69, no. 2, pp. 183–185, Feb. 2016. PubMed
A. Kutikov, M. C. Smaldone, R. G. Uzzo, M. Haifler, G. Bratslavsky, and B. C. Leibovich, “Renal Mass Biopsy: Always, Sometimes, or Never?,” European Urology, vol. 70, no. 3, pp. 403–406, Sep. 2016. PubMed
E. R. Plimack, R. L. Dunbrack, T. A. Brennan, M. D. Andrake, Y. Zhou, I. G. Serebriiskii, M. Slifker, K. Alpaugh, E. Dulaimi, N. Palma, J. Hoffman-Censits, M. Bilusic, Y.-N. Wong, A. Kutikov, R. Viterbo, R. E. Greenberg, D. Y. T. Chen, C. D. Lallas, E. J. Trabulsi, R. Yelensky, D. J. McConkey, V. A. Miller, E. A. Golemis, and E. A. Ross, “Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer,” European Urology, vol. 68, no. 6, pp. 959–967, Dec. 2015. PubMed
S. Ginzburg, R. Uzzo, J. Walton, C. Miller, D. Kurz, T. Li, E. Handorf, R. Gor, A. Corcoran, R. Viterbo, D. Y. T. Chen, R. E. Greenberg, M. C. Smaldone, and A. Kutikov, “Residual Parenchymal Volume, Not Warm Ischemia Time, Predicts Ultimate Renal Functional Outcomes in Patients Undergoing Partial Nephrectomy.,” Urology, vol. 86, no. 2, pp. 300–306, Aug. 2015. PubMed
B. Shuch, A. Amin, A. J. Armstrong, J. N. Eble, V. Ficarra, A. Lopez-Beltran, G. Martignoni, B. I. Rini, and A. Kutikov, “Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity,” European Urology, vol. 67, no. 1, pp. 85–97, Jan. 2015. PubMed
E. R. Plimack, J. H. Hoffman-Censits, R. Viterbo, E. J. Trabulsi, E. A. Ross, R. E. Greenberg, D. Y. T. Chen, C. D. Lallas, Y.-N. Wong, J. Lin, A. Kutikov, E. Dotan, T. A. Brennan, N. Palma, E. Dulaimi, R. Mehrazin, S. A. Boorjian, W. K. Kelly, R. G. Uzzo, and G. R. Hudes, “Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity,” J. Clin. Oncol., vol. 32, no. 18, pp. 1895–1901, Jun. 2014. PubMed
A. Minervini, M. Carini, R. G. Uzzo, R. Campi, M. C. Smaldone, and A. Kutikov, “Standardized Reporting of Resection Technique During Nephron-sparing Surgery: The Surface-Intermediate-Base Margin Score.,” European Urology, Jun. 2014. PubMed
A. Kutikov, P. Makhov, K. Golovine, D. J. Canter, M. Sirohi, R. Street, J. Simhan, R. G. Uzzo, and V. M. Kolenko, “Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer,” Urology, vol. 78, no. 4, pp. 968.e7–11, Oct. 2011. PubMed
A. Kutikov, M. C. Smaldone, B. L. Egleston, B. J. Manley, D. J. Canter, J. Simhan, S. A. Boorjian, R. Viterbo, D. Y. T. Chen, R. E. Greenberg, and R. G. Uzzo, “Anatomic Features of Enhancing Renal Masses Predict Malignant and High-Grade Pathology: A Preoperative Nomogram Using the RENAL Nephrometry Score,” European Urology, vol. 60, no. 2, pp. 241–248, Aug. 2011. PubMed
A. Kutikov, B. L. Egleston, Y.-N. Wong, and R. G. Uzzo, “Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram,” J. Clin. Oncol., vol. 28, no. 2, pp. 311–317, Jan. 2010. PubMed
A. Kutikov and R. G. Uzzo, “The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth,” The Journal of Urology, vol. 182, no. 3, pp. 844–853, Sep. 2009. PubMed
Dr. Kutikov is a member of the Philadelphia Inquirer's Health Advisory Panel.
You can find some of his selected Inquirer pieces here.
108 PATIENT COMMENTS
-
No Star Ratings Available
June 20, 2022
The PA was very articulate in her response to my questions
-
No Star Ratings Available
June 19, 2022
Dr. Kutikov is simply a great surgeon and provider.
-
5.0
June 18, 2022
Always a good experience when seeing Dr. Kutikov and his staff. Everyone is very caring.
-
5.0
June 12, 2022
The nurse and doctor made an uncomfortable snd embarrassing treatment very comforting. They helped me thru something I feared since my father had it done and put in my head what a horrible experience it was . I prayed I would never need it. Well, I did and the doctor and nurses were incredibly caring and professional. They made all the difference in the world and im very grateful I had Dr Kutikov and his team. They...were...awesome!
-
5.0
June 08, 2022
So glad I found Dr Kutikov
-
No Star Ratings Available
June 08, 2022
Dr was very kind, patient and personable.
-
5.0
May 26, 2022
The nurses that were there were excellent in making me feel comfortable. During the procedure the doctor was great in telling me through it.
-
5.0
May 24, 2022
Excellent care from this Doctors office
-
No Star Ratings Available
May 18, 2022
Excellent
-
No Star Ratings Available
May 14, 2022
Your staff are always friendly and helpful and also very knowledgeable
-
5.0
May 13, 2022
The best doctor in my life is Dr Kutikov. I am lucky as I get service health in his clinic and his staff.
-
5.0
April 30, 2022
Very professional and caring.
-
No Star Ratings Available
April 27, 2022
All good
-
No Star Ratings Available
April 23, 2022
Excellent quality care
-
5.0
April 19, 2022
Dr. Kutikov and his staff are wonderful. I feel lucky to have them taking care of me.
-
No Star Ratings Available
April 14, 2022
Good experience
-
No Star Ratings Available
March 21, 2022
I was very happy with my care and treatment.
-
5.0
March 18, 2022
Very Very satisfied with the care received.
-
No Star Ratings Available
March 16, 2022
The entire staff of Dr K's is above and beyond my expectations. Everyone was exceptional!!!
-
5.0
March 15, 2022
Love Dr. Kutikov and his staff!
LOAD MORE